Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pfizer

Related PFE
MedGenesis Announces Deal with Pfizer Related to Possible Treatments for Parkinson's
Benzinga's Weekend M&A Chatter
Martoma Hit with Nine-Year Prison Sentence (Fox Business)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Pfizer (NYSE: PFE), and raised its price target from $27.00 to $31.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Pfizer closed on Tuesday at $26.74.

Latest Ratings for PFE

DateFirmActionFromTo
Aug 2014Deutsche BankInitiates Coverage onBuy
Jul 2014BMO CapitalDowngradesOutperformMarket Perform
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters